Common use of Disclosure Controls and Procedures; Internal Controls Clause in Contracts

Disclosure Controls and Procedures; Internal Controls. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Form 10-K or Form 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of a date within ninety (90) days prior to the filing date of the Form 10-Q for the quarter ended September 30, 2002 (such date, the “Evaluation Date”). The Company presented in the Form 10-Q for the quarter ended September 30, 2002 the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is used in Item 307(b) of Regulation S-K under the Exchange Act) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal controls.

Appears in 4 contracts

Samples: Stock Purchase Agreement (Rita Medical Systems Inc), Stock Purchase Agreement (Rita Medical Systems Inc), Stock Purchase Agreement (Rita Medical Systems Inc)

AutoNDA by SimpleDocs

Disclosure Controls and Procedures; Internal Controls. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiariessubsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Form 10-K or Form 10-Q, as the case may be, is being prepared. The Company’s 's certifying officers have evaluated the effectiveness of the Company’s 's disclosure controls and procedures as of a date within ninety (90) days prior to the filing date of the Form 10-Q for the quarter ended September 30March 31, 2002 2003 (such date, the "Evaluation Date"). The Company presented in the Form 10-Q for the quarter ended September 30March 31, 2002 2003 the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s 's internal controls (as such term is used in Item 307(b) of Regulation S-K under the Exchange Act) or, to the Company’s 's knowledge, in other factors that could significantly affect the Company’s 's internal controls.

Appears in 1 contract

Samples: Securities Purchase Agreement (Avanir Pharmaceuticals)

Disclosure Controls and Procedures; Internal Controls. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiariessubsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Form 10-K or Form 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of a date within ninety (90) days prior to the filing date end of the Form 10-Q for the quarter ended September 30, 2002 periods covered by such reports (such date, the “Evaluation Date”). The Company presented in the Form 10-Q for the quarter ended September June 30, 2002 2008 the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is used in Item 307(b) of Regulation S-K under the Exchange Act) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal controls.

Appears in 1 contract

Samples: Subscription Agreement (Arrowhead Research Corp)

Disclosure Controls and Procedures; Internal Controls. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiariessubsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Form 10-K or Form 10-Q, as the case may be, is being prepared. The Company’s 's certifying officers have evaluated the effectiveness of the Company’s 's disclosure controls and procedures as of a date within ninety (90) days prior to the filing date of the Form 10-Q for the quarter ended September June 30, 2002 2003 (such date, the "Evaluation Date"). The Company presented in the Form 10-Q for the quarter ended September June 30, 2002 2003 the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s 's internal controls (as such term is used in Item 307(b) of Regulation S-K under the Exchange Act) or, to the Company’s 's knowledge, in other factors that could significantly affect the Company’s 's internal controls.

Appears in 1 contract

Samples: Securities Purchase Agreement (Avanir Pharmaceuticals)

AutoNDA by SimpleDocs

Disclosure Controls and Procedures; Internal Controls. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiariessubsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Form 10-K or Form 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of a date within ninety (90) days prior to the filing date end of the Form 10-Q for the quarter ended September 30, 2002 periods covered by such reports (such date, the “Evaluation Date”). The Company presented in the Form 10-Q for the quarter ended September June 30, 2002 2005 the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is used in Item 307(b) of Regulation S-K under the Exchange Act) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal controls.

Appears in 1 contract

Samples: Stock Purchase Agreement (Avanir Pharmaceuticals)

Disclosure Controls and Procedures; Internal Controls. The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its Subsidiariessubsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Form 10-K or Form 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures as of a date within ninety (90) days prior to the filing date end of the Form 10-Q for the quarter ended September 30, 2002 periods covered by such reports (such date, the “Evaluation Date”). The Company presented in the Form 10-Q K for the quarter year ended September 30, 2002 2005 the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is used in Item 307(b) of Regulation S-K under the Exchange Act) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal controls.

Appears in 1 contract

Samples: Stock Purchase Agreement (Avanir Pharmaceuticals)

Time is Money Join Law Insider Premium to draft better contracts faster.